Clinical trial
Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip…
NCT00154219 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00154219 |
|---|---|
| Title | Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis |
| Official title | A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Hip |
| Intervention type | Drug |
| Interventions | Lumiracoxib (drug) |
| Enrollment | 1,200 |
| Start date | Nov 1, 2004 |
| Primary completion | Oct 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | May 21, 2012 |
| Countries | Canada, Germany, Italy, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: